Therapeutic immune clearance of rabies virus from the CNS

Future Virology

Volumn 6, Issue 3, 2011, Pages 387-397

  Hooper, D Craig ^a   Roy, Anirban ^a   Kean, Rhonda B ^a   Phares, Timothy W ^a   Barkhouse, Darryll A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

neuroimmunity; rabies; rabies virus; vaccination; virus clearance

Indexed keywords

INTERFERON; MESSENGER RNA; NEUTRALIZING ANTIBODY; RABIES VACCINE;

ACTIVE IMMUNIZATION; ADAPTIVE IMMUNITY; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; DRUG CLEARANCE; GENE EXPRESSION; GENOTYPE; HUMAN; IMMUNE RESPONSE; INCUBATION TIME; INNATE IMMUNITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RABIES; RABIES VIRUS; REVIEW; SURVIVAL; T LYMPHOCYTE; VIRUS REPLICATION; WILD TYPE;

ANIMALIA; RABIES VIRUS;

EID: 79953321468     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.88     Document Type: Review

References (41)

1. Baer GM, Bellini WJ, Fishbein DB: Rhabdoviruses In: Virology (2nd Edition). Fields BN (Ed.). Raven press, NY, USA 883-930 (1990).
2. e sér. XIV 1431-1439 (1885). Report of first treatment of a rabies virus (RABV)-exposed individual using vaccination.
3. Messenger SL, Smith JS, Orciari LA, Yager PA, Rupprecht CE: Emerging pattern of rabies deaths and increased viral infectivity. Emerg. Infect. Dis. 9(2), 151-154 (2003).
4. Jackson AC: Human rabies and bat bites. Lancet 357, 1714 (2001).
5. Morimoto K, Patel M, Corisdeo S et al.: Characterization of a unique variant of bat rabies virus responsible for newly emerging human cases in North America. Proc. Natl Acad. Sci. USA 93, 5653-5658 (1996).
6. Gibbons RV: Cryptogenic rabies, bats, and the question of aerosol transmission. Ann. Emerg. Med. 39, 528-536 (2002).
7. Willoughby RE Jr, Tieves KS, Hoffman GM et al.: Survival after treatment of rabies with induction of coma. N. Engl. J. Med. 352(24), 2508-2514 (2005). Report of the first human recovery from clinical rabies in the absence of postexposure prophylaxis.
8. Centers for Disease Control and Prevention. 2004. Recovery of a patient from clinical rabies - Wisconsin, 2004. MMWR Morb. Mortal. Wkly Rep. 57(17), 460-462 (2004).
9. Roy A, Hooper DC: Lethal silver-haired bat rabies virus infection can be prevented by opening the blood-brain barrier. J. Virol. 81, 7993-7998 (2007).
10. Faber M, Li J, Kean RB, Hooper DC, Alugupalli KR, Dietzschold B: Effective preexposure and postexposure prophylaxis of rabies with a highly attenuated recombinant rabies virus. Proc. Natl Acad. Sci. USA 106(27), 11300-11305 (2009). First report of successful postexposure treatment of mice with a recombinant-engineered live - attenuated RABV.
11. Johnson N, Cunningham AF, Fooks AR: The immune response to rabies virus infection and vaccination. Vaccine 28(23), 3896-3901 (2010).
12. Roy A, Phares TW, Koprowski H, Hooper DC: Failure to open the blood-brain barrier and deliver immune effectors to the CNS tissues leads to the lethal outcome of Silver-haired bat rabies virus infection. J. Virol. 81(3), 1110-1118 (2007). Evidence from an experimental model that blood-brain barrier (BBB) integrity is maintained during a lethal RABV infection.
13. Wang ZW, Sarmento L, Wang Y et al.: Attenuated rabies virus activates, while pathogenic rabies virus evades, the host innate immune responses in the central nervous system. J. Virol. 79, 12554-12565 (2005).
14. Schneider LG, Cox JH, Müller WW, Hohnsbeen KP: Current oral rabies vaccination in Europe: an interim balance. Rev. Infect. Dis. 10(Suppl. 4), S654-S659 (1988).
15. Rupprecht CE, Dietzschold B, Cox JH, Schneider LG: Oral vaccination of raccoons (Procyon lotor) with an attenuated (SAD-B19) rabies virus vaccine. J. Wildl. Dis. 25(4), 548-554 (1989).
16. Hooper DC, Morimoto K, Bette M, Weihe E, Koprowski H, Dietzschold B: Collaboration of antibody and inflammation in clearance of rabies virus from the central nervous system. J. Virol. 72(5), 3711-3719 (1998).
17. Fabis MJ, Phares TW, Kean RB, Koprowski H, Hooper DC: Blood - brain barrier changes and cell invasion differ between therapeutic immune clearance of neurotrophic virus and CNS autoimmunity. Proc. Natl Acad. Sci. USA 105(40), 15511-15516 (2008).
18. Hooper DC, Bagasra O, Marini JC et al.: Prevention of experimental allergic encephalomyelitis by targeting nitric oxide and peroxynitrite: implications for the treatment of multiple sclerosis. Proc. Natl Acad. Sci. USA 94(6), 2528-2533 (1997).
19. Hooper, DC, Scott GS, Zborek A et al.: Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood - CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J. 14(5), 691-698 (2000).
20. Scott GS, Hooper DC: The role of uric acid in protection against peroxynitrite-mediated pathology. Med. Hypotheses 56(1), 95-100 (2001).
21. Hooper DC, Kean RB, Scott GS: The central nervous system inflammatory response to neurotropic virus infection is peroxynitrite dependent. J. Immunol. 167(6), 3470-3477 (2001).
22. Dietzschold B, Wunner WH, Wiktor TJ et al.: Characterization of an antigenic determinant of the glycoprotein which correlates with pathogenicity of rabies virus. Proc. Natl Acad. Sci. USA 80, 70-74 (1983).
23. Phares TW, Fabis MJ, Brimer CM, Kean RB, Hooper DC: A peroxynitrite-dependent pathway is responsible for blood - brain barrier permeability changes during a central nervous system inflammatory response: TNF-α is neither necessary nor sufficient. J. Immunol. 178(11), 7334-7343 (2007). Evidence from an experimental model that the clearance of attenuated RABV from CNS tissues is associated with functional changes in the BBB likely induced by IFN-γ.
24. Hooper DC, Phares TW, Fabis MJ, Roy A: The production of antibody by invading B cells is required for the clearance of rabies virus from the central nervous system. PLoS Negl. Trop. Dis. 3(10), E535 (2009). Demonstration that RABV clearance from the CNS is associated with antibody production by B cells infiltrating CNS tissues.
25. Roy A, Hooper DC: Immune evasion by rabies viruses through the maintenance of blood-brain barrier integrity. J. Neurovirol. 14(5), 401-411 (2008). Demonstration that the pathogenicity of different RABV correlates with the capacity of the host to deliver immune effectors to the CNS.
26. Phares TW, Kean RB, Mikheeva T, Hooper DC: Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system. J. Immunol. 176(12), 7666-7675 (2006). Evidence from an experimental model that the clearance of attenuated RABV from CNS tissues is associated with functional changes in the BBB.
27. Brzózka K, Finke S, Conzelmann KK: Identification of the rabies virus a/b interferon antagonist: phosphoprotein P interferes with phosphorylation of interferon regulatory factor 3. J. Virol. 79(12), 7673-7681 (2005).
28. Brzózka K, Finke S, Conzelmann KK: Inhibition of interferon signaling by rabies virus phosphoprotein P: activation-dependent binding of STAT1 and STAT2. J. Virol. 80(6), 2675-2683 (2006).
29. Hemachudha T, Wacharapluesadee S, Mitrabhakdi E, Wilde H, Morimoto K, Lewis RA: Pathophysiology of human paralytic rabies. J. Neurovirol. 11(1), 93-100 (2005).
30. Wiktor TJ, Doherty PC, Koprowski H: Suppression of cell-mediated immunity by street rabies virus. J. Exp. Med. 145(6), 1617-1622 (1977).
31. Jackson AC, Warrell MJ, Rupprecht CE et al.: Management of rabies in humans. Clin. Inf. Dis. 36, 60-63 (2003).
32. Jackson AC, Randle E, Lawrance G, Rossite JP: Neuronal apoptosis does not play an important role in human rabies encephalitis. J. Neurovirol. 14(5), 368-375 (2008).
33. Baloul L, Lafon M: Apoptosis and rabies virus neuroinvasion. Biochimie 85(8), 777-788 (2003).
34. Laothamatas J, Hemachuda T, Mitrabhajdi E, Wannakrairot, P, Tulayadaechonont S: MR imaging in human rabies. AJNR Am. J. Neuroradiol. 24(6), 1102-1109 (2003).
35. Centers for Disease Control and Prevention: Epidemiologic notes and reports human rabies -Minnesota. MMWR Morb. Mortal Wkly Rep. 57(17), 460-462 (2007).
36. Laothamatas J, Wacharapluesadee S, Lumlertdacha B et al.: Furious and paralytic rabies of canine origin: neuroimaging with virological and cytokine studies. J. Neurovirol. 14(2), 119-129 (2008).
37. Galea I, Bernardes-Silva M, Forse PA, van Rooijen N, Liblau RS, Perry VH: An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J. Exp. Med. 204(9), 2023-2030 (2007).
38. Neuwelt EA, Maravilla KR, Frenkel EP, Rapaport SI, Hill SA, Barnett PA: Osmotic blood - brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J. Clin. Invest. 64(2), 684-688 (1979).
39. Campbell M, Kiang AS, Kenna PF et al.: RNAi-mediated reversible opening of the blood-brain barrier. J. Gene Med. 10(8), 930-947 (2008).
40. Pardridge WM: Molecular Trojan horses for blood-brain barrier drug delivery. Discov. Med. 6(34), 139-143 (2006).
41. Baer GM, Shaddock JH, Williams LW: Prolonging morbidity in rabid dogs by intrathecal injection of attenuated rabies vaccine. Infect. Immun. 12(1), 98-103 (1975). First evidence from an experimental model that superinfection with an attenuated RABV can lead to survival from a wild-type RABV infection.